医学
耐受性
骨关节炎
内科学
物理疗法
关节软骨
不利影响
外科
病理
替代医学
作者
Gianni Belcaro,M R Cesarone,Claudia SCIPIONE,Valeria SCIPIONE,Morio Hosoi,Shu HU,Andrea Ledda,Beatrice Feragalli,Roberto Cotellese,David Cox
出处
期刊:Minerva surgery
[Edizioni Minerva Medica]
日期:2024-02-01
卷期号:79 (1)
标识
DOI:10.23736/s2724-5691.23.09967-7
摘要
BACKGROUND: The aim of this registry study was to evaluate the progress of osteoarthrosis (OA) symptoms after the intake of a new standardized supplement combination (Pycnogenol® + Centellicum®, both Horphag Research) in a group of subjects with OA.METHODS: Supplemented subjects took daily 150 mg Pycnogenol® + 450 mg Centellicum® for 6 months. Another comparable group of subjects using only standard management (SM) was included as a reference.RESULTS: Forty-five subjects with a mean age of 42 years completed the study, 25 in the supplemented group and 20 in the SM group. There were no safety problems or tolerability issues with the supplements. The two groups, SM and SM + Pycnogenol® + Centellicum® were comparable for age and clinical characteristics at inclusion. The two main ultrasound characteristics of cartilage, its thickness and surface-irregularity were more improved with the supplements. Pain scores, C reactive protein, the level of fitness and the use of extra pain killers (as rescue medication) were all significantly improved at 6 months with the supplement combination compared to SM (P<0.05). Plasma free radicals, pain-free walking distance on treadmill and erythrocyte sedimentation rate (ESR) were significantly improved with the supplements compared to SM.CONCLUSIONS: The morphological improvement - visible with ultrasound - correlates with a decrease in clinical symptoms and with a more efficient ambulation without pain. SM along with the Pycnogenol® Centellicum® combination are useful to avoid drug treatments that may expose patients to some side effects over time.
科研通智能强力驱动
Strongly Powered by AbleSci AI